Literature DB >> 25534280

Induction chemotherapy followed by surgery for advanced oesophageal cancer.

E L A Toxopeus1, S Talman2, A van der Gaast3, V M C W Spaander4, C M van Rij5, N C Krak6, K Biermann7, H W Tilanus2, R H J Mathijssen3, J J B van Lanschot2, B P L Wijnhoven2.   

Abstract

BACKGROUND: Patients with locoregionally advanced oesophageal tumours or disputable distant metastases are referred for induction chemotherapy with the aim to downstage the tumour before an oesophagectomy is considered. STUDY
DESIGN: Patients who underwent induction chemotherapy between January 2005 and December 2012 were identified from an institutional database. Treatment plan was discussed in the multidisciplinary team. Response to chemotherapy was assessed by CT. Survival was calculated using the Kaplan Meier method. Uni- and multivariable analyses were performed to identify prognostic factors for survival.
RESULTS: In total 124 patients received induction chemotherapy mainly for locoregionally advanced disease (n = 80). Surgery was withheld in 35 patients because of progressive disease (n = 16) and persistent unresectability (n = 19). The median overall survival of this group was 13 months (IQR: 8-19). The remaining 89 patients underwent surgery of which 13 still had unresectable tumour or distant metastases. Of the 76 patients that underwent an oesophagectomy, 50 patients had tumour free resection margins (66%) with an estimated 5-year survival of 37%. A positive resection margin (HR 4.148, 95% CI 2.298-7.488, p < 0.0001) was associated with a worse survival in univariable analysis, but only pathological lymph node status with increasing hazard ratio's (6.283-10.283, p = 0.001) remained significant after multivariable analysis.
CONCLUSION: Induction chemotherapy downstages the tumour and facilitates a radical oesophagectomy in patients with advanced oesophageal cancer. Pathological lymph node status is an independent prognostic factor for overall survival.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Advanced oesophageal cancer; Induction chemotherapy; Prognosis; Surgery

Mesh:

Year:  2014        PMID: 25534280     DOI: 10.1016/j.ejso.2014.11.043

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

Review 1.  The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.

Authors:  M J Valkema; B Mostert; S M Lagarde; B P L Wijnhoven; J J B van Lanschot
Journal:  Updates Surg       Date:  2022-07-14

2.  Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer.

Authors:  Eelke L A Toxopeus; Femke M de Man; Nanda Krak; Katharina Biermann; Annemieke J M Nieuweboer; Lena E Friberg; Esther Oomen-de Hoop; Jan J B van Lanschot; Joel Shapiro; Bas P L Wijnhoven; Ron H J Mathijssen
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

3.  The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients.

Authors:  Leni van Doorn; Marie-Rose B S Crombag; Hánah N Rier; Jeroen L A van Vugt; Charlotte van Kesteren; Sander Bins; Ron H J Mathijssen; Mark-David Levin; Stijn L W Koolen
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.